No products in the cart.
eSHA HEXAMITA Discus Disease Treatment 20ml
₹1,080.00 (incl. GST)
- eSHA HEXAMITA Discus Disease Treatment that combats disease in discus and all other Cichlids.
- Treatments includes Darking of color, Holes in the head, white stringy faeces, lesions at base of fins & skin decay.
- Effectively treats other bacterial and fungal infections.
- Prevents disease in newly acquired stock & Protects fish from secondary infections.
eSHA HEXAMITA Discus Disease Treatment 20ml
eSHA EXAMITA is unique treatment that combats disease in discus and all other Cichlids. Treatments includes Darking of color, Holes in the head, white stringy faeces, lesions at base of fins & skin decay.
- Effectively treats Hole in the head disease.
- Effectively treats other bacterial and fungal infections.
- Prevents disease in newly acquired stock.
- Protects fish from secondary infections.
eSHA HEXAMITA can also be used in conjunction with eSHA EXIT Anti -White-spot treatment and / or eSHA gdex – against skin flukes, gill flukes and tapeworms. This combination provides you with a broadly effective tool to solve and prevent most diseases your discus and Cichlids will encounter.
Composition/ml: Copper Sulphate 7.0 mg, Ethacridine Lactate 6.7 mg, Acriflavine 2.0 mg, Methylene Blue 6.3 mg in water.
Enclosed leaflet contains useful information. Read before use.
Standard Dosages
- Day 1 : 25 Drops / 100 Ltr.
- Day 2 : 12 Drops / 100 Ltr.
- Day 3 : 12 Drops / 100 Ltr.
- 20ml for max 800 Ltr. / 176 UK Gallons / 211 US Gallons
Warnings
- Veterinary medicine for animal (ornamental fish) treatment only.
- Keep bottle and leaflet in original packing.
- This product may stain if split.
- Keep out of reach of children and pets.
- Store frost-free in a cool, dark place.
- Do not use after expiration date.
- Disposal advice: see leaflet.
- Shelf life after first time opening: see leaflet.
- Contains copper, do not overdose.
This veterinary medicine is marketed in accordance with the Small Animal Exemption Scheme.
Reviews
There are no reviews yet.